Literature DB >> 23063485

Uridine adenosine tetraphosphate is a novel vasodilator in the coronary microcirculation which acts through purinergic P1 but not P2 receptors.

Zhichao Zhou1, Daphne Merkus, Caroline Cheng, Henricus J Duckers, A H Jan Danser, Dirk J Duncker.   

Abstract

Uridine adenosine tetraphosphate (Up4A) has been identified as an endothelium-derived contracting factor, which acts through purinergic P2X and P2Y receptors. Since the coronary vascular actions of Up4A are unknown, we investigated the vasoactive profile of Up4A in coronary microvessels, and studied the involvement of purinergic receptor subtypes. Studies were performed in isolated porcine coronary small arteries (diameter∼250 μm), with and without endothelial denudation, mounted on a Mulvany wire myograph. Purinergic receptor expression was assessed by real-time PCR. Up4A (10(-9)-10(-5) M) failed to induce contraction at basal tone, but produced concentration-dependent vasorelaxation in precontracted microvessels. Up4A was slightly less potent than adenosine, ATP, and ADP in producing vasorelaxation, but significantly more potent than UTP and UDP. mRNA expression of P2X(4), P2Y(1), P2Y(2), P2Y(4), P2Y(6) and A(2A), but not P2X(1), receptors was observed. Up4A-induced vasodilation was unaffected by non-selective P2 receptor antagonist PPADS, P2X(1) antagonist MRS2159, P2Y(1) antagonist MRS2179 and P2Y(6) antagonist MRS2578, but was markedly attenuated by non-selective P1 receptor antagonist 8PT and A(2A) antagonist SCH58261. Up4A-induced vasodilation was not affected by ectonucleotidase inhibitor ARL67156, suggesting that A(2A) stimulation was not the result of Up4A breakdown to adenosine. Up4A-induced vasodilation was blunted in denuded vessels; additional A(2A) receptor blockade further attenuated Up4A-induced vasodilation, suggesting that A(2A) receptor-mediated vasodilation is only partly endothelium-dependent. In conclusion, Up4A exerts a vasodilator rather than a vasoconstrictor influence in coronary microvessels, which is mediated via A(2A) receptors and is partly endothelium-dependent.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23063485     DOI: 10.1016/j.phrs.2012.09.011

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  17 in total

Review 1.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

Review 2.  Regulation of Coronary Blood Flow.

Authors:  Adam G Goodwill; Gregory M Dick; Alexander M Kiel; Johnathan D Tune
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

Review 3.  Constrictor prostanoids and uridine adenosine tetraphosphate: vascular mediators and therapeutic targets in hypertension and diabetes.

Authors:  Takayuki Matsumoto; Styliani Goulopoulou; Kumiko Taguchi; Rita C Tostes; Tsuneo Kobayashi
Journal:  Br J Pharmacol       Date:  2015-07-08       Impact factor: 8.739

4.  Uridine adenosine tetraphosphate is a novel neurogenic P2Y1 receptor activator in the gut.

Authors:  Leonie Durnin; Sung Jin Hwang; Masaaki Kurahashi; Bernard T Drumm; Sean M Ward; Kent C Sasse; Kenton M Sanders; Violeta N Mutafova-Yambolieva
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-23       Impact factor: 11.205

Review 5.  Uridine adenosine tetraphosphate and purinergic signaling in cardiovascular system: An update.

Authors:  Zhichao Zhou; Takayuki Matsumoto; Vera Jankowski; John Pernow; S Jamal Mustafa; Dirk J Duncker; Daphne Merkus
Journal:  Pharmacol Res       Date:  2018-12-13       Impact factor: 7.658

6.  Mechanisms underlying uridine adenosine tetraphosphate-induced vascular contraction in mouse aorta: Role of thromboxane and purinergic receptors.

Authors:  Zhichao Zhou; Changyan Sun; Stephen L Tilley; S Jamal Mustafa
Journal:  Vascul Pharmacol       Date:  2015-04-25       Impact factor: 5.773

7.  Enhanced uridine adenosine tetraphosphate-induced contraction in renal artery from type 2 diabetic Goto-Kakizaki rats due to activated cyclooxygenase/thromboxane receptor axis.

Authors:  Takayuki Matsumoto; Shun Watanabe; Ryusuke Kawamura; Kumiko Taguchi; Tsuneo Kobayashi
Journal:  Pflugers Arch       Date:  2013-07-31       Impact factor: 3.657

8.  Impaired Aortic Contractility to Uridine Adenosine Tetraphosphate in Angiotensin II-Induced Hypertensive Mice: Receptor Desensitization?

Authors:  Zhichao Zhou; Vishal R Yadav; Changyan Sun; Bunyen Teng; Jamal S Mustafa
Journal:  Am J Hypertens       Date:  2017-03-01       Impact factor: 2.689

9.  Involvement of NADPH oxidase in A2A adenosine receptor-mediated increase in coronary flow in isolated mouse hearts.

Authors:  Zhichao Zhou; Uthra Rajamani; Hicham Labazi; Stephen L Tilley; Catherine Ledent; Bunyen Teng; S Jamal Mustafa
Journal:  Purinergic Signal       Date:  2015-04-25       Impact factor: 3.765

10.  The enzymatic activity of the VEGFR2 receptor for the biosynthesis of dinucleoside polyphosphates.

Authors:  Vera Jankowski; Anna Schulz; Axel Kretschmer; Harald Mischak; Falko Boehringer; Markus van der Giet; Doreen Janke; Mirjam Schuchardt; Ralf Herwig; Walter Zidek; Joachim Jankowski
Journal:  J Mol Med (Berl)       Date:  2013-05-01       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.